Vimal Kavuru - Sep 25, 2023 Form 4 Insider Report for Acasti Pharma Inc. (ACST)

Role: Director, 10%+ Owner
Signature: /s/ Prashant Kohli, as attorney-in-fact
Stock symbol: ACST
Transactions as of: Sep 25, 2023
Transactions value $: $1,302,775
Form type: 4
Date filed: 9/27/2023, 07:46 PM
Previous filing: Jul 18, 2023
Next filing: Dec 20, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACST	Common Shares	Purchase	$1.25M	+676K	+132.18%	$1.85	1.19M	Sep 25, 2023	See footnote	F1, F2
holding	ACST	Common Shares						124K	Sep 25, 2023	See footnote	F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACST	Common Warrants (right to buy)	Purchase	$52.8K	+423K		$0.13^*	423K	Sep 25, 2023	Common Shares	423K	$3.00	See footnote	F2, F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These indirect holdings have been adjusted to give effect to the Company's 1-for-6 reverse stock split, effective July 10, 2023.
F2	These securities are held directly by Shore Pharma LLC, of which Vimal Kavuru is the sole member.
F3	Shares are held directly by Kottayil Grace Pharma LLC, of which Vimal Kavuru is a Manager. Mr. Kavuru is a Manager of Kottayil Grace Pharma LLC and shares voting and dispositive power with respect to the shares of Acasti Pharma Inc. directly held by Kottayil Grace Pharma LLC.
F4	The Common Warrants reported herein contain an exercise limitation prohibiting the holder from exercising the Common Warrants until such time as the holder and certain other related parties, would not beneficially own after any such exercise more than 19.99% of the then issued and outstanding common shares of the Company (the "Blocker"). Due to the Blocker, the Common Warrants beneficially owned indirectly by the holder are only currently partially exercisable.
F5	The Common Warrants will expire on the earlier of (i) the 60th day after the date of the acceptance by the U.S. Food and Drug Administration of a New Drug Application for the Company's product candidate GTX-104 or (ii) September 25, 2028.